Table 2 Comparison of the clinical outcomes of DAPA-HF and EMPEROR-REDUCED trials
From: SGLT2 inhibitors in heart failure with reduced ejection fraction
Clinical outcomes | EMPEROR-Reduced (N = 3730) | DAPA-HF (N = 4744) |
|---|---|---|
Empagliflozin versus Placebo HR (CI) | Dapagliflozin versus Placebo HR (CI) | |
Cardiovascular death or HHF | 0.75 (0.65–0.86) | 0.75 (0.65–0.85) |
Cardiovascular death | 0.92 (0.75–1.12) | 0.82 (0.69–0.98) |
HHF | 0.69 (0.59–0.81) | 0.70 (0.59–0.83) |